Lymphedema of breast cancer: risk factor and treatment

2015 ◽  
Vol 3 (4) ◽  
pp. 306-321
Author(s):  
Ana H. Losken ◽  
Elisa Mullan
Keyword(s):  
Breast Cancer ◽  
Risk Factor ◽  
Cancer Treatment ◽  
Breast Cancer Risk Factor ◽  
Breast Cancer Treatment ◽  
Breast Cancer Surgery ◽  
Secondary Lymphedema ◽  
Lymph Node Transfer ◽  
Arm Lymphoedema ◽  
Chronic Lymphedema

One of the well-known complication of breast cancer treatment is secondary lymphedema; an accumulation of protein-rich interstitial fluid due to the insufficient capacity of the lymphatic system. Lymphedema are affects about 20-30% of women following breast cancer treatment and the risk factors associated with lymphedema development after breast cancer surgery and or radiotherapy are not well established. Early diagnosis and treatment is considered important for successful management of breast cancer related arm lymphoedema. The objective of this study is to assess the value of risk factor and treatment modality of lymphedema. Electronic searches were conducted in MEDLINE®, EMBASE, CINAHL®, and Social Sciences Citation Index. Articles were included where researchers used qualitative research methods and when a comprehensive description of methods and the study's findings were provided. Among 1210 articles, 30-37% developed lymphedema and 45% associated with incresead body mass index (BMI), 53% related with higher stage of disease. Furthermore; 74% strongly step rise with the number of involved lymph nodes; 41% in comorbid diseases, and the time after surgery showed significant correlation with the development of lymphedema in 32%. Suction-assisted protein lipectomy (SAPL) has been shown to safely and effectively reduce the solid component of swelling in chronic lymphedema and microsurgery procedures, including lymphaticovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT), have been shown to be effective in the management of the fluid component of lymphedema and allow for decreased garment use.

scholarly journals EVALUATING THE RESPONSIVENESS OF THE FULLERTON ADVANCED BALANCE SCALE IN PATIENTS WITH LYMPHEDEMA SECONDARY TO BREAST CANCER SURGERY

Lymphology ◽  
2019 ◽  
Vol 52 (2) ◽  
Author(s):  
AK Yoosefinejad ◽  
M Hadadi ◽  
P Eslamloo
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Treatment Method ◽  
Breast Cancer Treatment ◽  
Breast Cancer Surgery ◽  
Minimal Detectable Change ◽  
Timed Up And Go ◽  
Secondary Lymphedema ◽  
Before And After ◽  
Volumetric Measurements

Lymphedema following surgical treatment for breast cancer can impair balance and predispose patients to falling. Fullerton Advanced Balance (FAB) Scale is a reliable and valid tool which can identify persons with different balance levels, but its responsiveness has not been investigated in patients with lymphedema secondary to breast surgery. Thirty women with stage 2 lymphedema secondary to breast cancer treatment received complex decongestive therapy (CDT) for 2 weeks as a routine treatment method. They were evaluated with FAB Scale and Timed Up and Go Test (TUGT), volumetric measurements and circumferential measurements of the upper limbs before and after CDT. A moderate change was found in FAB score after CDT (Cohen's effect size = 0.65). For FAB, the computed standard error of the mean was 0.85 and minimal detectable change was 2.33. Significant improvement in FAB score and TUGT results, and significant reductions in circumferential and volumetric measurements were seen after 2 weeks of CDT. The FAB score change showed a moderate correlation with circumference change and volumetric change (r = -0.41) but a very weak correlation with TUGT change (r = -0.1). The FAB Scale showed acceptable responsiveness in detecting treatment effects in patients with unilateral secondary lymphedema after breast cancer treatment.

Lymphangiectases on chronic lymphedema following breast cancer treatment

2019 ◽  
Vol 219 (3) ◽  
pp. 163-164
Author(s):  
L. Vergara de la Campa ◽  
E.R. Martínez Lorenzo ◽  
E. Molina Figuera
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Chronic Lymphedema

Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?

2008 ◽  
Vol 114 (2) ◽  
pp. 387-389 ◽  
Author(s):  
Vuk Stambolic ◽  
James R. Woodgett ◽  
I. George Fantus ◽  
Kathleen I. Pritchard ◽  
Pamela J. Goodwin
Keyword(s):  
Breast Cancer ◽  
Risk Factor ◽  
Cancer Treatment ◽  
Breast Cancer Treatment

scholarly journals Role of physiotherapy in supporting recovery from breast cancer treatment: a qualitative study embedded within the UK PROSPER trial

BMJ Open ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. e040116
Author(s):  
Sophie Rees ◽  
Bruno Mazuquin ◽  
Helen Richmond ◽  
Esther Williamson ◽  
Julie Bruce
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Exercise Intervention ◽  
Well Being ◽  
Breast Cancer Treatment ◽  
Breast Cancer Surgery ◽  
Sense Of Control ◽  
Post Surgery ◽  
The Uk ◽  
Behavioural Strategies

ObjectivesTo explore the experiences of women with breast cancer taking part in an early physiotherapy-led exercise intervention compared with the experiences of those receiving usual care. To understand physiotherapists’ experience of delivering the trial intervention. To explore acceptability of the intervention and issues related to the implementation of the Prevention Of Shoulder Problems (PROSPER) programme from participant and physiotherapist perspective.DesignQualitative semistructured interviews with thematic analysis.SettingUK National Health Service.ParticipantsTwenty participants at high risk of shoulder problems after breast cancer surgery recruited to the UK PROSPER trial (10 each from the intervention arm and control arm), and 11 physiotherapists who delivered the intervention. Trial participants were sampled using convenience sampling. Physiotherapists were purposively sampled from high and low recruiting sites.ResultsParticipants described that the PROSPER exercise intervention helped them feel confident in what their body could do and helped them regain a sense of control in the context of cancer treatment, which was largely disempowering. Control arm participants expressed less of a sense of control over their well-being. Physiotherapists found the exercise intervention enjoyable to deliver and felt it was valuable to their patients. The extra time allocated for appointments during intervention delivery made physiotherapists feel they were providing optimal care, being the ‘perfect physio’. Lessons were learnt about the implementation of a complex exercise intervention for women with breast cancer, and the issues raised will inform the development of a future implementation strategy.ConclusionsA physiotherapist-delivered early supported exercise intervention with integrated behavioural strategies helped women at risk of shoulder problems following breast cancer treatment to feel more confident in their ability to mobilise their arm post-surgery. A physiotherapist-delivered early supported exercise intervention with integrated behavioural strategies may address the sense of powerlessness that many women experience during breast cancer treatment.Trial registration numberISRCTN35358984.

Arm Lymphoedema, Shoulder Mobility and Muscle Strength after Breast Cancer Treatment ? A Prospective 2-year Study

2001 ◽  
Vol 3 (2) ◽  
pp. 55-66 ◽  
Author(s):  
Karin Johansson ◽  
Christian Ingvar ◽  
Maria Albertsson ◽  
Charlotte Ekdahl
Keyword(s):  
Breast Cancer ◽  
Muscle Strength ◽  
Cancer Treatment ◽  
Breast Cancer Treatment ◽  
Arm Lymphoedema

scholarly journals Caution Ahead: Research Challenges of a Randomized Controlled Trial Implemented to Improve Breast Cancer Treatment at Safety-Net Hospitals

2018 ◽  
Vol 14 (3) ◽  
pp. e158-e167
Author(s):  
Nina A. Bickell ◽  
Ajay Shah ◽  
Maria Castaldi ◽  
Theophilus Lewis ◽  
Alan Sickles ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Treatment ◽  
Implementation Research ◽  
Care Delivery ◽  
Safety Net ◽  
Breast Cancer Treatment ◽  
Breast Cancer Surgery ◽  
Key Informants ◽  
High Volume Hospital

Purpose: To implement and test a Web-based tracking and feedback (T&F) tool to close referral loops and reduce adjuvant breast cancer treatment underuse in safety-net hospitals (SNHs). Patient and Methods: We randomly assigned 10 SNHs, identified patients with new stage 1 to stage 3 breast cancer, assessed their connection with the oncologist, and relayed this information to surgeons for follow-up. We interviewed key informants about the tool’s usefulness. We conducted intention-to-treat and pre- and poststudy analyses to assess the T&F tool and implementation effectiveness, respectively. Results: Between the study start and intervention implementation, several hospitals reorganized care delivery and 49% of patients scheduled to undergo breast cancer surgery were ineligible because they already were in contact with an oncologist. One high-volume hospital closed. Despite randomization of hospitals, intervention (INT) hospitals had fewer white patients (5% v 16%; P = .0005), and more underuse (28% v 15%; P = .002) compared with usual care (UC) hospitals. Over time, INT hospitals with poorer follow-up significantly reduced underuse compared with UC hospitals (INT hospitals, from 33% to 9%, P = .001 v UC hospitals, from 15% to 11%, P = .5). There was no difference in underuse (9% at INT hospitals, 11% at UC hospitals; P = .8). Hospitals with better follow-up (odds ratio, 0.85; 95% CI, 0.73 to 0.98) had less underuse. In settings with poor follow-up and tracking approaches, key informants found the tool useful. The rapidly changing delivery landscape posed significant challenges to this implementation research. Conclusion: A T&F tool did not significantly reduce adjuvant underuse but may help reduce underuse in SNHs with poor follow-up capabilities. Inability to discern T&F effectiveness is likely due to encountered challenges that inform lessons for future implementation research.

Sign in / Sign up

Export Citation Format

Share Document